<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Актуальные проблемы медицины</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.52575/2687-0940-2025-48-2-146-155</article-id><article-id pub-id-type="publisher-id">238</article-id><article-categories><subj-group subj-group-type="heading"><subject>ВНУТРЕННИЕ БОЛЕЗНИ</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Распространенность гипотиреоза среди лиц, перенесших &lt;/strong&gt;&lt;strong&gt;COVID&lt;/strong&gt;&lt;strong&gt;-19&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Prevalence of Hypothyroidism among COVID-19 Survivors&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Белоусова</surname><given-names>Оксана Николаевна</given-names></name><name xml:lang="en"><surname>Belousova</surname><given-names>Oksana N.</given-names></name></name-alternatives><email>belousova_on@bsuedu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Чупаха</surname><given-names>Марина Владимировна</given-names></name><name xml:lang="en"><surname>Chupakha</surname><given-names>Marina V.</given-names></name></name-alternatives><email>Chupakha@bsuedu.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Нестеренко</surname><given-names>Марина Вадимовна</given-names></name><name xml:lang="en"><surname>Nesterenko</surname><given-names>Marina V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Белоусов</surname><given-names>Дмитрий Павлович</given-names></name><name xml:lang="en"><surname>Belousov</surname><given-names>Dmitry P.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2025</year></pub-date><volume>48</volume><issue>2</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2025/2/АПМ_2025_Том_48__2_146-155.pdf" /><abstract xml:lang="ru"><p>Целью данной работы было определить количество случаев впервые выявленного гипотиреоза, а также установить связь между развитием декомпенсации гипотиреоза и ранее перенесенной инфекцией COVID-19 среди пациентов, наблюдающихся у врача-эндокринолога за последние три года. В рамках исследования проведен анализ данных амбулаторных карт 317 пациентов с диагнозом &amp;laquo;Первичный гипотиреоз в исходе аутоиммунного тиреоидита в стадии компенсации/декомпенсации&amp;raquo;, находящихся под наблюдением врача-эндокринолога Поликлиники НИУ&amp;nbsp;&amp;laquo;БелГУ&amp;raquo; в период с января 2021&amp;nbsp;г. по декабрь 2023 г. Оценка нарушений эндокринной функции щитовидной железы основывалась на комплексной диагностике пациентов. Полученные результаты проходили статистическую обработку при помощи программы IBM SPSS Statistic 26. Отмечен значительный рост количества случаев впервые выявленного гипотиреоза в 2023 г. по сравнению с 2021 г., 26,7&amp;nbsp;% и 10,7&amp;nbsp;% соответственно, а также пациентов с декомпенсацией гипотиреоза среди ранее наблюдавшихся у эндокринолога по поводу данного заболевания. Установлено более тяжёлое течение гипотиреоза в исходе аутоиммунного тиреоидита среди пациентов, перенесших инфекцию СOVID-19. Перенесенная новая коронавирусная инфекция в анамнезе является неоспоримым фактором риска развития патологии со стороны щитовидной железы. Оценка функции щитовидной железы рекомендована пациентам, перенесшим COVID-19, с целью ранней диагностики нарушений, в том числе среди пациентов с гипотиреозом, уже наблюдающихся у эндокринолога. Своевременная диагностика данных изменений позволит улучшить прогноз для каждого пациента.</p></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to determine the number of cases of newly diagnosed hypothyroidism, as well as to establish a link between the development of decompensated hypothyroidism and a previous COVID-19 infection among patients followed up by an endocrinologist over the past three years. As part of the study, the authors analyzed data from outpatient records of 317 patients diagnosed with &amp;ldquo;autoimmune thyroiditis, manifest hypothyroidism&amp;rdquo;, who were under the supervision of an endocrinologist at Belgorod State University Polyclinic from January 2021 to December 2023. The assessment of endocrine dysfunction of the thyroid gland was based on a comprehensive clinical, laboratory and instrumental diagnosis of patients. The obtained results were statistically processed using the IBM SPSS Statistic 26 program. The study revealed a significant increase in the number of cases of newly diagnosed hypothyroidism in 2023 compared to 2021, 26.7&amp;nbsp;% and 10.7&amp;nbsp;%, respectively, as well as in the number of patients with decompensated hypothyroidism among those previously observed by an endocrinologist for this disease. A more severe course of hypothyroidism in the outcome of autoimmune thyroiditis was established among patients who had suffered from COVID-19 infection. A history of new coronavirus infection is an undeniable risk factor for the development of thyroid pathology. Examination of thyroid function is mandatory in patients who have suffered a new coronavirus infection, including among patients with hypothyroidism with autoimmune thyroiditis who have been followed up by an endocrinologist for a long time.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гипотиреоз</kwd><kwd>тиреотропный гормон</kwd><kwd>трийодтиронин</kwd><kwd>тироксин</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypothyroidism</kwd><kwd>thyroid-stimulating hormone</kwd><kwd>triiodothyronine</kwd><kwd>thyroxine</kwd><kwd>COVID-19</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Климчук А.В., Белоглазов В.А., Яцков И.А., Дворяньчиков Я.В. 2022. Эндокринные нарушения на фоне COVID-19 и при постковидном синдроме. Ожирение и метаболизм. 19(2): 206&amp;ndash;212. doi: 10.14341/omet12853</mixed-citation></ref><ref id="B2"><mixed-citation>Bornstein S.R, Dalan R., Hopkins D., Mingrone G., Boehm B.O. 2020. Endocrine and Metabolic Link to Coronavirus Infection. Nat. Rev. Endocrinol. 16(6): 297&amp;ndash;8. doi:&amp;nbsp;10.1038/s41574-020-0353-9</mixed-citation></ref><ref id="B3"><mixed-citation>Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., Ma K., Xu D., Yu H., Wang H., Wang T., Guo W., Chen J., Ding C., Zhang X., Huang J., Han M., Li S., Luo X., Zhao J., Ning Q. 2020. Clinical Characteristics of 113 Deceased Patients with Coronavirus Disease 2019: Retrospective Study. BMJ. 26(368):1091. doi: 10.1136/bmj.m1091</mixed-citation></ref><ref id="B4"><mixed-citation>Chen Y., Li X., Dai Y., Zhang J. 2022. The Association between COVID-19 and Thyroxine Levels: A Meta-Analysis. Front Endocrinol (Lausanne). 12: 779692. doi: 10.3389/fendo.2021.779692</mixed-citation></ref><ref id="B5"><mixed-citation>Giovanella L., Ruggeri R.M., Ovсariсek P.P., Campenni A., Treglia G., Deandreis D. 2021. Prevalence of Thyroid Dysfunction in Patients with COVID-19: A Systematic Review. Clin Transl Imaging. 9(3): 233&amp;ndash;240. doi: 10.1007/s40336-021-00419-y</mixed-citation></ref><ref id="B6"><mixed-citation>Giovanella L., Ruggeri R.M., Petranoviс Ovсariсek P., Campenni A., Treglia G., Deandreis D. 2021. SARS-CoV-2-Related Thyroid Disorders: A Synopsis for Nuclear Medicine Thyroidologists. Eur. J. Nucl. Med. Mol. Imaging. 48(6): 1719&amp;ndash;1723. doi: 10.1007/s00259-021-05316-0</mixed-citation></ref><ref id="B7"><mixed-citation>Gong J., Wang D.K., Dong H., Xia Q.S., Huang Z.Y., Zhao Y., Chen X., Yuan F., Li J.B., Lu F.E. 2021. Prognostic Significance of Low TSH Concentration in Patients with COVID-19 Presenting with Non-Thyroidal Illness Syndrome. BMC Endocr. Disord. 21(1): 111. doi: 10.1186/s12902-021-00766-x</mixed-citation></ref><ref id="B8"><mixed-citation>Hanley B., Naresh K.N., Roufosse C., Nicholson A.G., Weir J., Cooke G.S., Thursz M., Manousou P., Corbett&amp;nbsp;R., Goldin R., Al-Sarraj S., Abdolrasouli A., Swann O.C., Baillon L., Penn R., Barclay W.S., Viola P., Osborn M. 2020. Histopathological Findings and Viral Tropism in UK Patients with Severe Fatal COVID-19: A Post-Mortem Study. Lancet Microbe. 1(6): 245&amp;ndash;253. doi: 10.1016/S2666-5247(20)30115-4</mixed-citation></ref><ref id="B9"><mixed-citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Muller M.A., Drosten C., Pohlmann S. 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 181(2): 271&amp;ndash;280. doi: 10.1016/j.cell.2020.02.052</mixed-citation></ref><ref id="B10"><mixed-citation>Jackson C.B., Farzan M., Chen B., Choe H. 2022. Mechanisms of SARS-CoV-2 Entry into Cells. Nat. Rev. Mol. Cell. Biol. 23(1): 3&amp;ndash;20. doi: 10.1038/s41580-021-00418-x</mixed-citation></ref><ref id="B11"><mixed-citation>Li M.Y., Li L., Zhang Y., Wang X.S. 2020. Expression of the SARS-CoV-2 Cell Receptor Gene ACE2 in a Wide Variety of Human Tissues. Infect Dis Poverty. 9(1): 45. doi:&amp;nbsp;10.1186/s40249-020-00662-x</mixed-citation></ref><ref id="B12"><mixed-citation>Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga&amp;nbsp;K., Greenough T.C., Choe H., Farzan M. 2003. Angiotensin-Converting Enzyme 2 is a Functional Receptor for the SARS Coronavirus. Nature. 426(6965): 450&amp;ndash;4. doi: 10.1038/nature02145</mixed-citation></ref><ref id="B13"><mixed-citation>Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O. 2020. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 5(7): 831&amp;ndash;840. doi: 10.1001/jamacardio.2020.1286</mixed-citation></ref><ref id="B14"><mixed-citation>Rotondi M., Coperchini F., Ricci G., Denegri M., Croce L., Ngnitejeu S.T., Villani L., Magri F., Latrofa F., Chiovato L. 2021. Detection of SARS-COV-2 Receptor ACE-2 mRNA in Thyroid Cells: A Clue for COVID-19-Related Subacute Thyroiditis. J. Endocrinol. Invest. 44(5): 1085&amp;ndash;1090. doi: 10.1007/s40618-020-01436-w</mixed-citation></ref><ref id="B15"><mixed-citation>Tee L.Y., Harjanto S., Rosario B.H. 2021. COVID-19 Complicated by Hashimoto&amp;#39;s Thyroiditis. Singapore Med. J. 62(5): 265. doi: 10.11622/smedj.2020106</mixed-citation></ref><ref id="B16"><mixed-citation>Zou R., Wu C., Zhang S., Wang G., Zhang Q., Yu B., Wu Y., Dong H., Wu G., Wu S., Zhong Y. 2020. Euthyroid Sick Syndrome in Patients with COVID-19. Front Endocrinol (Lausanne). 11: 566439. doi: 10.3389/fendo.2020.566439</mixed-citation></ref></ref-list></back></article>